Dividend Distribution - The company plans to distribute a cash dividend of 2.5 RMB per 10 shares, totaling 193.6942 million RMB, based on a total share capital of 77,477.68 million shares as of September 23, 2021[4]. - The proposed cash dividend for 2022 is 2.00 RMB per 10 shares, amounting to 154.95536 million RMB, with a cash dividend payout ratio of 50.71% for 2021[4]. - The company does not plan to issue bonus shares or increase capital from reserves[4]. Financial Performance - The company's operating revenue for 2021 was CNY 8,824,602,491.38, representing a 6.08% increase compared to CNY 8,319,101,227.07 in 2020[17]. - The net profit attributable to shareholders for 2021 was CNY 687,578,239.44, a decrease of 21.62% from CNY 877,182,412.47 in 2020[17]. - The net cash flow from operating activities for 2021 was negative CNY 226,783,526.46, a decline of 131.18% compared to CNY 727,254,373.22 in 2020[19]. - The total assets at the end of 2021 were CNY 13,646,713,835.03, an increase of 25.06% from CNY 10,912,247,412.27 at the end of 2020[19]. - The basic earnings per share for 2021 was CNY 0.95, down 24.60% from CNY 1.26 in 2020[20]. - The weighted average return on equity for 2021 was 10.55%, a decrease of 6.31 percentage points from 16.86% in 2020[20]. Risk Management - The company has detailed various risks and countermeasures in its management discussion and analysis section[7]. - The company emphasizes the importance of investor awareness regarding potential risks in forward-looking statements[5]. - The company faces risks from macroeconomic fluctuations that could impact downstream industry demand, potentially affecting its profitability[116]. - The company is exposed to raw material price volatility, particularly for phenolic and furan resins, which could lead to increased production costs and reduced gross margins[117]. Corporate Governance - The board of directors and senior management have confirmed the authenticity, accuracy, and completeness of the annual report[2]. - The company has maintained a robust governance structure, ensuring compliance with laws and regulations, and protecting shareholder interests through transparent practices[124]. - The governance structure includes independent directors who diligently fulfill their duties, contributing to the company's strategic oversight[126]. - The company has established mechanisms to prevent the controlling shareholder from misusing company funds, ensuring financial independence[125]. Environmental Responsibility - The company has installed 15 sets of online monitoring facilities for air emissions, ensuring compliance with environmental standards[169]. - The company has implemented a comprehensive waste management strategy, including the proper disposal of general and hazardous solid waste[167]. - The company has continuously reduced the waste generation per ton of product year by year through extensive emission reduction efforts[175]. - The company has increased the proportion of clean energy in its structure and accelerated the electrification and intelligence of various departments to reduce carbon emissions[176]. Research and Development - The company holds 777 authorized intellectual properties, including 528 invention patents, reflecting its strong R&D capabilities[50]. - The company has developed over 800 varieties of multi-purpose phenolic resin products across 10 major series[36]. - Research and development expenses rose by 5.66% to ¥360,940,439.29, reflecting increased investment in R&D[58]. - The company has invested significantly in R&D for new materials and technologies, but faces risks related to the commercialization and market adoption of these innovations[121]. Market Expansion - The company is expanding its market presence, targeting a 10% increase in market share in the next year[134]. - The company aims to enhance its product and platform development, focusing on upgrading existing products and rapidly developing new ones in line with market trends[115]. - The company is focusing on developing high-value-added oil products and chemical raw materials as per the national industry guidelines[82]. Employee Engagement and Training - A total of 30 training sessions were conducted in 2021, targeting various employee levels, including recent graduates and key personnel, to enhance skills and promote a learning culture[154]. - The company has established a comprehensive compensation system that includes base salary, performance bonuses, year-end bonuses, allowances, and benefits to attract and retain talent[153]. Shareholder Relations - All resolutions proposed during the three shareholder meetings held in 2021 were approved without any rejections, indicating strong shareholder support[129]. - The company has implemented an effective performance evaluation and incentive mechanism for senior management, linking assessments to profit and economic value added[160]. Strategic Investments - The company made a total of four external investments during the reporting period, including a 51% stake in Shandong Shengquan Rail Transit Equipment Co., Ltd. with an investment of ¥51 million[106]. - The company established a wholly-owned subsidiary, Daqing Shengquan Cellulose Products Co., Ltd., with an investment of ¥50 million[107].

Financial Performance - The company's operating revenue for Q1 2022 was ¥2,226,248,064.81, representing a year-on-year increase of 16.53%[2] - The net profit attributable to shareholders for Q1 2022 was ¥125,483,616.25, showing a decrease of 21.81% compared to the same period last year[2] - Basic earnings per share for Q1 2022 were ¥0.16, down 30.43% from the previous year[2] - Total operating revenue for Q1 2022 reached RMB 2,226,248,064.81, an increase of 16.5% compared to RMB 1,910,514,789.76 in Q1 2021[15] - Net profit for Q1 2022 was RMB 128,669,840.71, a decrease of 23% from RMB 166,951,462.84 in Q1 2021[16] - The company reported a total profit of RMB 148,332,519.18 for Q1 2022, down from RMB 194,754,093.10 in Q1 2021[16] Cash Flow - The net cash flow from operating activities was -¥825,003,851.76, a decline of 58.06% year-on-year[2] - Cash flow from operating activities in Q1 2022 was RMB 1,099,791,285.65, an increase from RMB 1,042,241,941.78 in Q1 2021[17] - Operating cash inflow totaled approximately ¥1.22 billion, slightly up from ¥1.21 billion in the previous year, indicating a year-over-year increase of about 0.9%[18] - Operating cash outflow increased to approximately ¥2.05 billion from ¥1.74 billion, representing a year-over-year increase of about 17.9%[18] - Net cash flow from operating activities was negative at approximately -¥825 million, worsening from -¥522 million in the previous year[18] - Cash flow from investing activities was negative at approximately -¥150 million, slightly improved from -¥151 million year-over-year[19] - Cash inflow from financing activities totaled approximately ¥695 million, up from ¥684 million, reflecting a year-over-year increase of about 1.4%[19] - Net cash flow from financing activities was positive at approximately ¥75.56 million, compared to ¥48.96 million in the previous year, showing a significant improvement[19] - The ending cash and cash equivalents balance was approximately ¥1.12 billion, down from ¥920 million year-over-year[19] - The company reported a decrease in cash flow due to foreign exchange fluctuations, amounting to approximately -¥23.81 million, compared to -¥5.40 million in the previous year[19] Assets and Liabilities - Total assets at the end of Q1 2022 amounted to ¥13,683,544,975.63, a slight increase of 0.27% from the end of the previous year[3] - The equity attributable to shareholders was ¥8,072,085,418.42, reflecting a year-on-year increase of 1.62%[3] - Accounts receivable increased significantly to RMB 1,791,486,763.18 from RMB 1,345,275,163.47, marking an increase of about 33.1%[12] - Inventory rose to RMB 1,694,106,427.21 compared to RMB 1,519,165,371.63, reflecting an increase of approximately 11.5%[12] - Total current liabilities increased to RMB 2,991,242,712.10 from RMB 2,649,052,512.40, indicating a rise of about 12.9%[13] - Long-term borrowings decreased to RMB 1,746,412,783.16 from RMB 2,211,928,062.87, a reduction of approximately 21.0%[13] - The company's total equity attributable to shareholders rose to RMB 8,072,085,418.42 from RMB 7,943,323,060.48, an increase of about 1.6%[14] Strategic Focus - The company plans to enhance its market expansion strategies and invest in new product development, although specific figures are not provided[11] - The company is actively monitoring its financial health and adjusting its strategies in response to market conditions[11] Other Financial Metrics - Non-recurring gains and losses for the period totaled ¥5,326,932.45, after accounting for tax and minority interests[5] - The weighted average return on net assets decreased by 1.23 percentage points to 1.57%[3] - Research and development expenses for Q1 2022 amounted to RMB 99,510,918.14, slightly up from RMB 97,726,754.11 in Q1 2021[16] - Financial expenses decreased significantly to RMB 22,646,533.60 in Q1 2022 from RMB 55,994,614.50 in Q1 2021[16] - Other comprehensive income after tax for Q1 2022 was RMB 50,894.31, compared to a loss of RMB 2,186,747.01 in Q1 2021[16] - The company experienced a net loss of RMB 39,327,171.36 in credit impairment losses for Q1 2022[16] - The company's net profit margin for the first quarter of 2022 is not explicitly stated but is a key focus for future performance evaluation[11]

Financial Performance - The company's operating revenue for Q3 2021 was ¥2,277,585,614.49, a decrease of 6.14% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2021 was ¥153,863,279.58, down 38.86% year-on-year[2]. - The basic earnings per share for Q3 2021 was ¥0.22, reflecting a decline of 39.64% compared to the previous year[4]. - The company reported a net cash flow from operating activities of -¥1,902,297,196.07 for the year-to-date period[4]. - The company attributed the decline in profits to the high profits from mask sales in the same period last year due to the pandemic[7]. - The total comprehensive income attributable to the parent company's owners for Q3 2021 was CNY 525,384,236.55, a decrease from CNY 666,094,246.92 in Q3 2020, representing a decline of approximately 21.1%[18]. - The company's basic and diluted earnings per share for Q3 2021 were both CNY 0.75, down from CNY 0.95 in Q3 2020, representing a decline of approximately 21.1%[18]. - Net profit for the third quarter was ¥539,944,035.49, down from ¥672,050,450.62, representing a decline of approximately 19.6%[17]. Assets and Liabilities - The total assets at the end of Q3 2021 amounted to ¥13,106,568,025.56, representing an increase of 20.11% from the end of the previous year[4]. - The total current assets as of September 30, 2021, amounted to 6,781.60 million RMB, compared to 5,559.24 million RMB in the previous year[13]. - The company reported a significant increase in long-term fixed assets, reaching 2,944.10 million RMB compared to 2,094.83 million RMB in the previous year[13]. - The total liabilities amounted to ¥5,175,742,472.74, slightly down from ¥5,179,393,841.66, indicating a decrease of about 0.1%[14]. - The company's total liabilities increased, with a notable rise in borrowings, reflecting ongoing financing needs and potential strategic investments[22]. - Total liabilities reached approximately ¥5.18 billion, with current liabilities at ¥2.72 billion and non-current liabilities at ¥2.45 billion[24]. Equity - The equity attributable to shareholders increased by 38.82% year-on-year, reaching ¥7,778,128,011.41[4]. - The equity attributable to shareholders increased to ¥7,778,128,011.41 from ¥5,603,168,773.78, showing a growth of approximately 38.8%[15]. - Shareholders' equity totaled approximately ¥5.73 billion, with equity attributable to the parent company at ¥5.60 billion[25]. Revenue Segments - The company's revenue increased by 0.95% year-on-year despite a significant decline in the health protection products segment[11]. - Sales revenue from health protection products was 232.55 million RMB, with a gross profit of 59.08 million RMB during the reporting period[11]. - Excluding health protection products, other main business segments achieved sales revenue of 6,029.29 million RMB, a year-on-year growth of 43.22%[11]. - The gross profit from other main business segments was 1,485.39 million RMB, reflecting a year-on-year increase of 33.73%[11]. Cash Flow - The net cash flow from operating activities for the first nine months of 2021 was -CNY 1,902,297,196.07, compared to -CNY 93,072,992.54 in the same period of 2020, indicating a significant deterioration in cash flow[20]. - The net cash flow from investing activities for the first nine months of 2021 was -CNY 920,598,125.47, compared to -CNY 404,467,165.52 in the same period of 2020, indicating increased cash outflows for investments[21]. - The net cash flow from financing activities for the first nine months of 2021 was CNY 2,214,139,700.40, a significant increase from CNY 440,405,896.69 in the same period of 2020, showing improved financing activities[21]. - The total cash and cash equivalents at the end of Q3 2021 were CNY 943,821,327.71, compared to CNY 671,472,501.07 at the end of Q3 2020, indicating an increase of approximately 40.5%[21]. Research and Development - Research and development expenses increased to ¥290,108,745.80 from ¥235,451,235.39, marking a rise of about 23.2%[17]. - The company is focusing on high-performance resins, composite materials, and biomass refining to enhance its industrial ecosystem[11]. Initial Public Offering - The company completed its initial public offering in August 2021, contributing to the increase in equity[7].